Biological Obstacles for Identifying In Vitro- In Vivo Correlations of Orally Inhaled Formulations
- PMID: 31284402
- PMCID: PMC6680885
- DOI: 10.3390/pharmaceutics11070316
Biological Obstacles for Identifying In Vitro- In Vivo Correlations of Orally Inhaled Formulations
Abstract
Oral inhalation of drugs is the classic therapy of obstructive lung diseases. In contrast to the oral route, the link between in vitro and in vivo findings is less well defined and predictive models and parameters for in vitro-in vivo correlations are missing. Frequently used in vitro models and problems in obtaining in vivo values to establish such models and to identify the action of formulations in vivo are discussed. It may be concluded that major obstacles to link in vitro parameters on in vivo action include lack of treatment adherence and incorrect use of inhalers by patients, variation in inhaler performance, changes by humidity, uncertainties about lung deposition, and difficulties to measure drug levels in epithelial lining fluid and tissue. Physiologically more relevant in vitro models, improvement in inhaler performance, and better techniques for in vivo measurements may help to better understand importance and interactions between individual in vitro parameters in pulmonary delivery.
Keywords: composition of epithelial lining fluid; inhalers; lung deposition; patient compliance; pharmaceutical aerosols; pulmonary drug delivery.
Conflict of interest statement
The author declares no conflict of interest.
Figures
Similar articles
-
Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.Comput Biol Med. 2017 May 1;84:247-253. doi: 10.1016/j.compbiomed.2016.10.025. Epub 2016 Nov 3. Comput Biol Med. 2017. PMID: 27836120
-
An Exploration of Factors Affecting In Vitro Deposition of Pharmaceutical Aerosols in the Alberta Idealized Throat.J Aerosol Med Pulm Drug Deliv. 2019 Dec;32(6):405-417. doi: 10.1089/jamp.2019.1531. Epub 2019 Aug 16. J Aerosol Med Pulm Drug Deliv. 2019. PMID: 31418632
-
Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs.Int J Pharm. 2019 Feb 10;556:45-56. doi: 10.1016/j.ijpharm.2018.11.072. Epub 2018 Dec 7. Int J Pharm. 2019. PMID: 30529665 Review.
-
Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.Eur J Pharm Sci. 2020 Nov 1;154:105508. doi: 10.1016/j.ejps.2020.105508. Epub 2020 Aug 21. Eur J Pharm Sci. 2020. PMID: 32836137
-
Delivery Technologies for Orally Inhaled Products: an Update.AAPS PharmSciTech. 2019 Feb 19;20(3):117. doi: 10.1208/s12249-019-1314-2. AAPS PharmSciTech. 2019. PMID: 30783904 Review.
Cited by
-
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment.Nat Commun. 2025 Apr 5;16(1):3251. doi: 10.1038/s41467-025-58568-x. Nat Commun. 2025. PMID: 40185752 Free PMC article.
-
A Monoclonal Human Alveolar Epithelial Cell Line ("Arlo") with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections.Adv Sci (Weinh). 2023 Mar;10(8):e2207301. doi: 10.1002/advs.202207301. Epub 2023 Feb 7. Adv Sci (Weinh). 2023. PMID: 36748276 Free PMC article.
-
Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus.Pharmaceutics. 2020 Feb 11;12(2):145. doi: 10.3390/pharmaceutics12020145. Pharmaceutics. 2020. PMID: 32053877 Free PMC article.
-
A novel in vitro high-content imaging assay for the prediction of drug-induced lung toxicity.Arch Toxicol. 2024 Sep;98(9):2985-2998. doi: 10.1007/s00204-024-03800-8. Epub 2024 May 28. Arch Toxicol. 2024. PMID: 38806719 Free PMC article.
-
Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models.Sci Rep. 2025 Mar 19;15(1):9515. doi: 10.1038/s41598-025-94476-2. Sci Rep. 2025. PMID: 40108297 Free PMC article.
References
-
- Silva A., Tavares M., Aguiar-Ricardo A. Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery. J. Nanopart. Res. 2014;16:2602. doi: 10.1007/s11051-014-2602-0. - DOI
-
- Pulmonary Drug Delivery Market. [(accessed on 2 April 2019)]; Available online: https://www.gilberttechnologies.eu/our-business/
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources